The MHRA rejection is a material setback for Traws' lead influenza asset, likely pressuring the stock. Monitor for updates on backup candidate advancement and any FDA interaction regarding the existing clinical hold on TXM. Cash runway through Q1 2027 provides some buffer but does not offset the pipeline blow.
Price Chart
Executive Summary
Traws Pharma disclosed that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred after a negative review by the UK's MHRA. The company is advancing backup candidates and has cash runway through Q1 2027, but the lead influenza program faces a significant regulatory setback.
Key Facts
- Phase 2a human influenza challenge study for tivoxavir marboxil deferred due to negative MHRA review
- Company advancing backup influenza antiviral candidates with TXM's pharmacokinetic profile but without mutagenic potential
- Cash runway extends to Q1 2027
- TXM retains potential for emergency use in bird flu outbreak and prevention in high-risk populations per management
Financial Impact
Lead pipeline program (tivoxavir marboxil) for influenza faces indefinite delay; no financial figures provided in filing
Risk Factors
- Lead influenza program (tivoxavir marboxil) faces indefinite clinical delay
- Backup candidates are preclinical and unproven
- Existing FDA clinical hold on TXM remains unresolved
- Cash runway only through Q1 2027 with no revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-073593 |
| Document: tm2617872d1_ex99-1.htm | 0001104659-26-073593 |
| Document: 0001104659-26-073593-index-headers.html | 0001104659-26-073593 |
| Document: 0001104659-26-073593-index.html | 0001104659-26-073593 |
| Document: 0001104659-26-073593.txt | 0001104659-26-073593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | — | awaiting T+20 | — | — |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers